

ANNUAL REPORT 2020

Australasian Sleep Association



www.sleep.org.au



Index

- 4 Board 2019-2020
- 5 President
- 6 Chief Executive Officer
- 7 Clinical Chair
- 8 Conference Chair
- 9 Education Chair
- 10 Finance Chair
- 11 Membership Chair
- 13 Research Chair
- 15 New Zealand Branch President
- 16 ANZSSA Representative
- 17 Financial Report



114/30 Campbell Street
Blacktown NSW 2148
T +61 (0)2 9920 1968
F +61 (0)2 9672 3884
E admin@sleep.org.au
www.sleep.org.au
ABN 51 138 032 014

Board 2019-2020

President	A/Prof Alan Young	Finance Chair	A/Prof Nathaniel Marshall
Past President:	Prof Peter Eastwood	Membership Chair	Dr Jennifer Walsh
Clinical Chair	A/Prof Sutapa Mukherjee	Research Chair	A/Prof Denise O'Driscoll
Conference Chair	Dr Andrew Gikas	NZ Branch President	Dr Angela Campbell
Education Chair	A/Prof Ching Li Chai-Coetzer	Independent Director	Ms Teanau Roebuck (representing ANZSSA)

Vision

Provision of world standard research, education and training, and establishment of clinical standards to ensure clinical best practice in sleep medicine resulting in an informed community with healthy sleep practices.

Mission

To lead and promote sleep health and sleep science in Australia and New Zealand and to facilitate the professional development of its members by providing education and training, fostering research and establishing clinical standards within the field.

Goals

In order to achieve its Mission, the ASA will:

- Promote **Education and Training** in sleep health and sleep science within its membership and the other health related professions
- Foster **Research** in sleep health and sleep science
- Establish **Clinical Standards** within the profession and industry
- Be the recognised **Voice** of sleep expertise
- **Advocate** for the professional development of members
- Keep members and the community **Informed** about all matters relating to sleep health and sleep science
- Provide **Services** to members

To say this has been a challenging first year as ASA President would be an understatement! We have all faced unprecedented circumstances related to the first wave of the COVID-19 pandemic, further compounded by an additional second wave in my home state of Victoria. During challenging times, a strong, supportive and unified team are more important than ever. I am proud to say that our members have risen to meet this challenge.

Appreciating the difficulties of running a sleep service during the pandemic, the ASA has provided clear guidance with recommendations on the closing and reopening of sleep laboratories and appropriate infection control. Staff and patient safety have been paramount, balancing this with the economic impact. We held a series of online forums with members to share concerns and disseminate these recommendations. This dynamic process is ongoing with resources available on the COVID-19 section of our website. We have maintained excellent lines of communication with the Australian Government Deputy Chief Medical Officer Dr Nick Coatsworth and the ASA is well represented on the National COVID-19 Clinical Evidence Taskforce.

We have faced significant financial challenges over the last 12 months and will continue to do so going forward. The Board has had to make some difficult decisions to ensure the financial sustainability of our organisation. The changeover in CEO, declining conference income over the last few years and the effects of the pandemic on our share equity and membership numbers have had a huge impact. We have cut spending on advocacy, media communications, office costs and implemented stringent monthly reviews of our financial position with an aim to return to cost neutral by June 2022. We also made the correct decision to postpone Sleep DownUnder in Brisbane from 2020 to 2021 in light of current travel restrictions. We have replaced this with Sleep Week in 2020, our first ever virtual annual meeting, which is shaping up as a very successful event.

There have also been many highlights amidst the gloom of the pandemic. We welcomed our new CEO, Marcia Balzer, who has a wealth of experience working in not-for-profit organisations. In the most difficult circumstances imaginable she has played a pivotal role



Annual Report President

in guiding the ASA through these difficult times. We have expanded our webinar program to provide frequent, high quality online education for our members. We are developing a sleep accreditation program for dentists and in the process of signing an affiliation agreement with the Sleep Research Society that will provide our members with free access to prestigious journal SLEEP. It was an honour to present the Distinguished Achievement Award to Dr Murray Johns at an online ceremony in September. The following reports from our CEO and Board members will outline many other achievements.

There are too many people to thank individually on behalf our Association, but I'd like to make special mention of a few. The Clinical Committee, led by Sutapa Mukherjee, the Finance Committee, led by Nat Marshall, the entire ASA Board, members of the Councils, Marcia Balzer and our office staff, Kara Nicholson and Mischka Yates – thanks to all of you for your tireless work and support for which we are truly grateful. Finally, a fond farewell to Stephanie Blower who has been the cornerstone of our association for 20 years, Helen Burdette for her hard work and dedication in the office and Past President Peter Eastwood for his incredible leadership, invaluable advice and mentoring of me in this role.

A/Prof Alan Young
President

It was a real honour to start my new role halfway through the 2019-2020 financial year, and to become part of the great community that is the ASA.

Having worked in many professional associations in the course of my career, the ASA immediately impressed me with how hard-working and productive the volunteer committees and working groups are. I realised very soon after arriving that the collaborative work happening in the ASA's committees and working groups is the powerhouse behind the organisation.

I was enjoying getting to know the many volunteers and their work when suddenly, within two short months of my arrival, everything changed!

Between March and June 2020, the association saw more changes than had been experienced for a good long while. Perhaps the most significant of these was the postponement of Sleep DownUnder 2020. The development of a two-year strategy to address the association's financial vulnerabilities was critically important given that the postponement of the 2020 conference was anticipated to exacerbate those vulnerabilities. Another key emphasis of the strategy is to continue adapting to change brought by the pandemic so that the ASA can thrive in the long term.

I was not the only new staff member during the year, which usually means saying goodbye as well as hello. Stephanie Blower's farewell celebration was a powerful tribute to her 20 years with ASA, and we also said farewell to Mareta Ikimata who departed at the end of her fixed-term contract. Helen Burdette made a long-planned transition to focus solely on her role with the Sleep Health Foundation. Helen is still part of our office team, but no longer working in an ASA role. In early June, we welcomed Kara Nicholson as our new Sponsorship and Events Manager to help deliver our virtual events over the coming year. Our continuing team member, Mischka Yates, has helped us navigate all these changes with enormous grace and good humour.



Annual Report Chief Executive Officer

The arrival of the pandemic tested our ability to move quickly and flexibly to adapt to changing circumstances. The Clinical Committee consulted with members to provide written advice on the operation of sleep services in the new environment, while the Education and Conference committees set to work to develop new online education programs. Our webinar program and preparations for Sleep Week were underway by May, and members responded enthusiastically to the challenge of organising two new education programs. Our staff team have been working from home since late March, and we expect that this will continue indefinitely.

There are many changes still ahead – some we are planning for, and no doubt many we don't yet know about. I'm looking forward to facing these challenges alongside the amazing staff, Board and volunteers who together are the ASA.

Ms Marcia Balzer
Chief Executive Officer



Annual Report Clinical Chair

Clinical Committee: *Sutapa Mukherjee (Chair), Linda Schachter (Deputy Chair), Roy Beran, David Cunnington, Brett Duce, Garun Hamilton, Craig Hukins, Stuart MacKay, Christopher Pantin, Melissa Ree, Bandana Saini, Nur Sulaiman, John Swieca, Patryk Szulakowski, Julie Tolson, Jacob Twiss, Moya Vandeleur, John Wheatley, Brendon Yee*

The major responsibilities of the Clinical Committee are:

- 1 To establish and promote best practice standards in sleep medicine;
- 2 To promote the highest quality of care for patients; and
- 3 To advocate for public funding for sleep medicine services.

It has been a tremendously busy and challenging year. During the past 12 months the Clinical Committee has taken an active role in providing responses and advice to various organizations and professional bodies. Whilst this is time consuming it is essential to ensure we keep sleep medicine a priority and meet our major responsibilities as a committee.

COVID-19

All sleep services have been impacted by the COVID-19 pandemic and I have been extremely grateful to all ASA members who I called on for advice during the initial stages. Since March the Clinical Committee has met monthly rather than bi-monthly with frequent email exchanges in between. This has facilitated rapid communication to members in the development of consensus guidelines for how to manage sleep services during the pandemic with clear advice on when to cease sleep services.

Several virtual discussion forums for members were convened to inform these guidelines with attention to infection control and potential risk to staff and patients. The gradual reopening of sleep services around Australia and New Zealand also occurred and we reviewed those decisions in Victoria with the increased case numbers. There have been significant changes in the landscape of sleep services due to the pandemic and it is likely these changes will persist indefinitely. Department of Health data shows that home sleep studies outweigh laboratory studies by a factor of 2:1 currently in Australia.

In April 2020 ASA wrote to the Federal Health minister, Greg Hunt, requesting temporary item numbers for home sleep testing for adults and children and this was unsuccessful. Due to the disproportionate impact of COVID-19 on paediatric sleep medicine (which does not have access to home polysomnography for children) we have commenced discussions with the Department of Health on how to secure Medicare funding for home sleep testing for children, with a likely Medical Services Advisory Committee application in the near future.

Since March 2020 Alan Young and I have been involved in the National COVID-19 Clinical Evidence Taskforce (<https://covid19evidence.net.au>) which meets weekly with clinical representatives from 29 member organisations. The Taskforce seeks to support health care professionals with continually-updated evidence-based clinical guidelines for COVID-19. Alan Young sits on the Steering Committee and I am the Co-Chair of the Guidelines Leadership Group. It has been a privilege to be involved in this continuing national effort.

Medicines Subcommittee

In July 2020 a minor submission to the Pharmaceutical Benefits Advisory Committee was submitted requesting a change in the initial treatment phase and clinical criteria for the prescription of modafinil/armodafinil for treatment of narcolepsy to reflect contemporary guidelines on narcolepsy management. The outcome of this submission has been deferred and we await the final decision. This subcommittee continue to advocate strongly for better access to medications for patients, especially those with narcolepsy and idiopathic hypersomnia.

Sleep services accreditation

The sleep services accreditation process within NATA continues to run smoothly, albeit virtually for much of 2020 due to COVID-19.

ASA/TSANZ working party on overnight oximetry

This working party continues to progress the Medical Services Advisory Committee application for Medicare funding of overnight oximetry for respiratory and sleep indications.

Sleep medicine in New Zealand

We continue to provide support to our New Zealand colleagues with emphasis on better funding for sleep medicine in New Zealand and improved accessibility to sleep studies and medications for sleep disorders.

Position statements

This year the Australasian commentary on the AASM Manual for the Scoring of Sleep was published in *Sleep and Biological Rhythms* and the surgical management of obstructive sleep apnoea position statement has just been accepted for publication in *Respirology*. The guidelines for long term ventilation in children are in the final stages prior to submission and work has begun on updating the adult guidelines for polysomnography (2014) to reflect current practice.

There is ongoing work on other guidelines including CPAP treatment for OSA, restless legs syndrome/periodic limb movements of sleep, evidence-based behavioural treatment approaches for sleep problems and evidence-based therapies for snoring. There is an urgent need for national standards for ventilator-dependent patients and a working party is being developed (with TSANZ) to address this important issue.

New members

Some long-term members have left the committee this year and I thank them for their service. We welcome new members Nur Sulaiman, David Cunnington, Patryk Szulakowski, Brett Duce and Julie Tolson who will add to the committee's diversity and clinical representation.

Finally, I would like to thank all the members of the Clinical Committee, the subcommittees and working parties for their hard work during the past 12 months. It has been a great experience to work closely with all of you.

A/Prof Sutapa Mukherjee

Clinical Chair



Annual Report Conference Chair

Conference Committee: *Andrew Gikas (Chair), Jasneek Chawla (Deputy Chair), Maree Barnes, Janet Cheung, Chin Moi Chow, Scott Coussens, David Cunnington, Amal Mohd Dameer, Barbara Galland, Nicole Grivell, Leon Kitipornchai, Trung Ngo, Gemma Paech, Teanau Roebuck, Charli Sargent, Belinda Suthers, Andrew Vakulin, Moya Vandeleur, Alexander Wolkow*

The Conference Committee of the ASA is tasked with making the ASA/ANZSSA Annual Scientific Meeting the premier sleep meeting in our region.

On 16-20 October 2019, Sleep DownUnder returned to Sydney for the first time since 2011 at the redeveloped Sydney International Convention Centre, a world class venue that will no doubt host our meetings again. Overall, the 31st Annual Scientific Meeting was a success that saw a total of 811 members, sponsors and invited guests attend and a total of 237 scientific abstracts submitted. The conference continues to grow with the post-conference survey showing that 88% of responders rated the meeting as very good or excellent. Who would have known it would be the last time we would meet face to face for some time and the turmoil that 2020 would bring?

In early March it was becoming apparent that the 2020 Brisbane meeting would be postponed. To revisit what we missed, the Brisbane meeting was more than two years in the planning as we were to combine Sleep DownUnder with the meetings of the International Paediatric Sleep Association and the International Surgical Sleep Society, which was set to have been our biggest event on record. A significant amount of work had been put into this combined meeting and I would like to acknowledge Maree Barnes, Jasneek Chawla,

Rosemary Horne and Stuart MacKay for their respective roles in planning for this. We may have cancelled this event but no doubt we have the ability and desire to host international events on our shores one day soon.

As the whole world embraces the new normal of social distancing, this year we have planned an online meeting – Sleep Week – which will not replace a face to face meeting but will go some way in helping us to stay connected with a strong program that has been formulated and developed with the help of each of our Councils. With just a few months to organise, the team at the ASA office led by our CEO Marcia Balzer with the help of Kara Nicholson and Mischka Yates have done an excellent job in making it possible to host a week of sleep content online.

A meeting like this does not happen without significant behind the scenes work from our members. Firstly, a big thank you to a number of members and council representatives who have answered the call to volunteer their time to help shape ideas for online sessions. I would like to sincerely thank the members of the Conference Committee who have attended monthly meetings. They have worked hard to provide a scientific program that reflects the diversity of the ASA membership so please also take the time to thank them in person if you can!

I hope the Committee have enjoyed their contribution this year and that they stay on for next year but if there is a vacancy and you are thinking of joining the Conference Committee next year, please feel free to nominate via your Council.

We rely heavily on our sponsors and exhibitors to help us achieve our goals. I would like to thank and acknowledge the generous support of all our sponsors. Thank you especially to our two platinum sponsors in Phillips and Resmed, plus supporters Compumedics, Fisher & Paykel Healthcare, Aspen Pharmacare and Temple Healthcare who have all contributed to make Sleep Week possible.

Dr Andrew Gikas

Conference Chair



Annual Report Education Chair

Education Committee: *Ching Li Chai-Coetzer (Chair), Amy Reynolds (Deputy Chair), Sarah Blunden, Catherine Buchan, Jill Dorrian, Andrew Gikas, Helen Gilbert, Jessica Kennedy, Sally Powell, Shyamala Pradeepan, Rob Shea, Alan Young*

The COVID-19 pandemic created numerous challenges throughout 2020. It has forced us to consider how we can adapt to continue delivering a high standard of education to the members of the Australasian Sleep Association and others involved in the delivery of sleep disorders services. With the sudden need for social distancing, lockdowns, work-from-home orders, and cancellation of face-to-face meetings, we saw a swift move towards increased utilisation of online platforms to enable effective communication and education delivery.

One of the many ways in which the ASA has responded to these challenges has been the enhancement of our webinar series (which previously consisted of only 4-5 sessions per year) to a regular, fortnightly offering. The fortnightly webinar program has been running very successfully, attracting on average around 60 registrants per session, covering a broad range of topics which have been relevant to the diverse range of health professionals, scientists and other craft groups served by the ASA. We thank all of the ASA members who have generously provided their time in chairing, delivering, attending and actively participating in these interactive presentations. Sleep Week, a virtual program scheduled over 4 days in late October, is another way that the ASA will be stepping up to the challenge of the COVID-19 pandemic to enable ongoing educational and scientific networking opportunities for its members.

While a few of the Education subcommittees and working parties have had a brief hiatus in activity due to

COVID-19, groups have largely remained active throughout 2020. Some of the highlights are as follows:

- **The GP Education Subcommittee** (co-chaired by Alan Young and Jill Dorrian) has continued to work closely with the NHMRC Primary Care Centre of Research Excellence group to revise the RACGP Modules on Insomnia and Obstructive Sleep Apnea which are currently hosted on the RACGP GP Learning website. A podcast delivered by Alan Young was also recorded for HealthEd 2020 on the topic of sleep and mental health.
- **The Advanced Trainee Education Subcommittee** (chaired by Jessica Kennedy) has been working to ensure that Sleep Medicine trainees will have an opportunity to present their research projects results during a dedicated session for advanced trainees during Sleep Week. It is also reviewing existing ASA website resources with the aim of re-cataloguing and improving access to educational materials for trainees and other ASA members.
- **The Behavioural Management of Sleep Disorders Education Committee** (chaired by Amy Reynolds) has been exploring pathways to introduce sleep education into postgraduate learning opportunities for psychologists, and will be working closely with the ASA Clinical Committee on a position statement on behavioural therapies for sleep disorders.
- **The Nursing Education Subcommittee** (co-chaired by Catherine Buchan and Sally Powell) is continuing to analyse data from its nursing workforce survey, and has recently reached out to the Australian College of Nursing to discuss how sleep education can be better incorporated into the nursing model.
- **The Pharmacy Education Subcommittee** (chaired by Helen Gilbert) is looking at ways to promote sleep education to pharmacists and plan to be involved in upcoming ASA webinars.
- **The Indigenous Sleep Health Working Party** (chaired by Sarah Blunden) is continuing to work on the Indigenous Sleep Health Report which will focus on the needs of Indigenous Australians, while a separate report will be developed relating to Maori populations by New Zealand sleep researchers.
- **The Dental Sleep Medicine Accreditation Working Party** (chaired by Andrew Gikas) is progressing with creation of a multiple-choice examination which will form part of its proposed dental sleep medicine accreditation process.

A/Prof Ching Li Chai-Coetzer

Education Chair



Annual Report Finance Chair

Finance Committee: *Nathaniel Marshall (Chair), Marcia Balzer, Romola Bucks, Peter Eastwood, Robert Estcourt, Christopher Worsnop, Alan Young*

The Association continues to be in a sound financial position. It does, however, have significant but manageable issues with its financial performance and cash flow management. These will require continued attention and action going forward.

Despite the major financial perturbations caused by the pandemic, our investment portfolio held its value. Readers of the balance sheet will have noticed its value there has fallen as we have had to fund a cash flow shortfall through withdrawal from the investment portfolio. Despite this withdrawal (\$150,482), and despite the effects of the pandemic on parts of our portfolio, the value of our investment is currently still more (\$841,305) than our initial outlay of \$800,000.

This year's financial performance has seen us post a deficit of \$151,474 which was better than the deficit budgeted for 2019-2020 of \$190,765. This shortfall has been funded by drawing on our retained earnings built up over the history of the association. The Board approved this deficit as an extraordinary measure to address the requirements of changing to a new CEO. These included substantial recruitment costs, and the departing CEO taking significant accrued leave after her final day in the office. This deficit also reflects some underlying structural issues that had been crystallised by a move to a full accrual accounting approach on 1 July 2019.

Our cash management has also required some attention this year as our on-hand cash reserves were exhausted by the ongoing operating deficit that had been offset in

the profit and loss by the performance of our investment portfolio. The ongoing cash and financial performance management issue will be to match operating revenues from non-investment activities to the operating expenses of the association's day-to-day activities. Previously this mismatch had been obscured by the income generated by the investment portfolio which was re-invested.

Our revenues over the period being reported have not been meaningfully impacted by the pandemic yet as our revenue streams come in during the first half of the financial year through memberships and conference profits. Our membership receipts remained steady in 2019-20 and were acceptably similar to that budgeted. However, our conference in October 2019 did not earn the budgeted revenue.

My thanks again go out to the team at JB Were, Mark Leslie and Robert Estcourt who provide us with expert advice on how to manage the ASA's financial reserves and scholarship funds sustainably into the future. They have helped steer us through the most recent period and we will continue to work with them to provide income to support the membership services of the association.

A/Prof Nathaniel Marshall

Finance Chair



Annual Report Membership Chair

Membership Committee: *Jennifer Walsh (Chair), Jayne Carberry, Daniel Judge, Nicole Lovato, Kathleen Maddison, Gorica Micic, Amal Osman, Alexander Sweetman, Philip Terrill*

Councils Subcommittee: *Jennifer Walsh (Chair), Barbara Galland, Honey Heussler, Luke Katahanas, Nicole Lovato, Hailey Meaklim, Gemma Paech, Stephanie Rainey-Smith, Amy Reynolds, Nick Stow, John Swieca, Kate Sutherland, Prerna Varma, Andrew Webster, Christopher Worsnop*

Membership Numbers


The number of ASA members has increased from 2019, with 951 members as of 30 June 2020. The continued growth of the ASA membership, despite the COVID-19 induced personal challenges that many members have faced, is testament to the recognition and value of the ASA as the leading professional organisation supporting a variety of clinical and research specialties within the broad field of sleep.

The majority of the ASA's members are located in Australia with just over 50% from Victoria and New South Wales and another 36% from the remaining Australian states/territories and almost 10% of members based in New Zealand.


State meetings

One of the key objectives of the Membership Committee over the past year was to help facilitate the state-based meetings. The state meetings provide an opportunity for members to meet regularly throughout the year to network locally and hear about research and clinical education that might be locally relevant.

ASA Membership 2003-2020



ASA Member Location 2020



Monthly state meetings have been successfully running in Victoria for many years thanks to dedication of Matthew Naughton and Teanau Roebuck (ANZSSA representative). Over the past few years, the Membership Committee has been working with state meeting organisers in the remaining states to solidify these meetings on their local calendars also.

Thanks to the hard work of Amy Reynolds and her team in South Australia (Sally Ferguson, Jill Dorrian, Robert Adams, Sutapa Mukherjee and Hannah Scott), Roo Killick and Carla Evans in New South Wales and Kath Maddison in Western Australia, state meetings have been progressing with one meeting held in each of New South Wales and Western Australia in the second half of 2019.

Unfortunately, COVID-19 stifled plans for further meetings in 2020 although South Australia and Western Australia each managed to sneak in a face to

face meeting prior to restrictions on gatherings. Western Australia also hosted a webinar on Sleep During COVID at the start of the 2020 webinar series. Feedback from the state meetings is always overwhelmingly positive so we look forward to further meetings when gathering restrictions ease.

Sub-committee of councils

There are 10 ASA councils which play an important role in unifying members with similar research and clinical interests. Through webinars, seminars and social and mainstream media, the councils contribute to the education of ASA members as well as the wider community regarding their specialty. There are numerous roles within each council, each being important for the smooth running of the council. The Membership Committee has refined the Toolbox for Councils, which is available on the website and outlines

the different roles. All members are encouraged to look at how they can be more actively involved in their council(s) of interest. Thank you to all members who have contributed to the councils over the past year.

Communication platforms

Communication with members continues to be largely through electronic newsletters which have been streamlined for ease of reading thanks to Marcia and Mischka. The private Facebook group currently moderated by Amal Osman has over 230 members and the public Facebook page has over 1,500 followers.

The website continues to be great source of information and is continually being tweaked, improved and updated. Members are encouraged to contribute to all means of communication if they have information that is relevant to other members or the public.

Thank you to the Membership Committee, Secretariat, and all members who have contributed to the ASA over the past year. Your input has been welcomed and appreciated. I look forward to continued engagement in the year to come.

Dr Jennifer Walsh
Membership Chair



Annual Report Research Chair

Research Committee: *Denise O'Driscoll (Chair), Romola Bucks, Angela D'Rozario, Jennifer Cori, Scott Coussens, Brad Edwards, Danny Eckert, Rosemary Gibson, Camilla Hoyos, Roo Killick, Fergal O'Donoghue, Andrew Vakulin, Jennifer Walsh, David Wang*

The Research Committee has continued to work on a number of key strategic goals to achieve our overall mission to strengthen and encourage high quality sleep research in Australia and New Zealand. I'd like to personally thank the committee members for their hard work and enthusiasm this year. In addition, I would like to thank the ASA office, particularly Mischka Yates, for the support this year.

Awards

Despite the challenges imposed on us all due to the pandemic restrictions, we received a high volume of applications for the 2020 New Investigator Award. The committee reviewed all applications and made the tough decision to select the top six finalists. We look forward to hearing their presentations at Sleep Week 2020 in competition for the top prize.

Our other prestigious awards have all been postponed for 2020. This decision was carefully considered, and was taken in light of the financial implications for the association, and practically speaking, the travel awards would not be feasible at this time. The ASA is committed to supporting sleep research and the advancement of our junior researchers and we look forward to resuming the Research Awards at the appropriate time.

In the meantime, we have been active in streamlining

the submission process and post-award reporting. This streamlined process will enable applicants to apply directly via the submission portal on the ASA website for the relevant grant or award, and upload any supporting documentation requested. Post-award reporting will also allow us to highlight the key achievements of our awardees on the ASA website. Excitingly, the resumption of awards will include a new travel award (\$5,000) made possible with the generous support from Fisher & Paykel Healthcare. Details on this new award will be available next year.

Research advocacy

We continue in our political advocacy efforts to raise the profile of sleep research and the need for more research funding in this area. This year we submitted an NHMRC Targeted Call for Research application. The proposal titled "Understanding and improving sleep health in Indigenous Australians" included supporting documentation from a number of key health services. This application would not have been made possible without the extraordinary work and commitment of the Indigenous Sleep Health Working Party: Sarah Blunden, Stephanie Yiallourou, YuSun Bin and Fatima Yaqoot. At the time of writing, we still eagerly await the outcome of this submission.

In addition, we prepared an ASA submission to the public consultation on the Aged Care and Ageing Mission - a medical research package focused on dementia, ageing and aged care funded through the Medical Research Future Fund. Our submission served to highlight the need of adding sleep research to the roadmap for the government's research commitment on dementia, ageing and aged care.

Sleep research was hindered this year with the rapid introduction of pandemic restrictions, particularly in Victoria. To provide guidance on this issue, we developed a joint statement from the Research and Clinical Committees titled *Recommendations for research polysomnography during COVID-19 pandemic* to provide guidance on the resumption of research sleep studies.

Research funding

While research funding remains very challenging, particularly with low success rates for federally funded competitive grants, there have been several key successes from our members that warrant celebration. This includes a successful NHMRC Ideas Grant for A/Prof Sean Cain and colleagues titled "Circadian mechanisms for antidepressant medication treatment".

In addition, several very prestigious and highly competitive Investigator Grants were awarded to our members including Prof Ronald Grunstein, Prof Danny Eckert, Dr Stephanie Rainey-Smith and Prof Rosemary Horne. Congratulations to all these members and their colleagues.

Sleep Week

As in previous years we will be hosting a dedicated Early Career Researcher Session at Sleep Week. This free session entitled "Consumer Engagement and the Search for Philanthropic Grants" will include presentations and discussion from three guest speakers - Dr Shantel Duffy, Dr Samantha Rowbotham and Professor Sinthia Bosnic-Anticevich. This will be a key session for junior researchers starting their career and the search for research funding.

The ASA mentorship program has taken a pause for 2020 with the next intake of mentees scheduled to occur in conjunction with the ASA conference in 2021 – a year where we can hopefully catch up again in the "new normal". Till then, stay safe.

A/Prof Denise O'Driscoll

Research Chair



Annual Report New Zealand Branch

New Zealand Branch Executive Committee:

Angela Campbell (Chair), Sonia Cherian, Andrew Davies, Barbara Galland, Rachelle Love, Karyn O’Keeffe, Sally Powell, Bronwyn Sweeney, Patryk Szulakowski, Jacob Twiss

Despite our annual scientific meeting (Sleep in Aotearoa) being postponed to 10-11 May 2021 due to COVID-19, it has been a busy year for the New Zealand Branch.

At our AGM three committee members stepped down, and we would like to thank Dr Ken Whyte and Prof Alister Neill for their input over many years to the committee. Thank you to Dr Dan Garner who also resigned from the committee this year.

The vacant positions in the committee have been taken up by Dr Rachelle Love from Christchurch, Dr Patryk Szulakowski from Tauranga and Dr Sonia Cherian from Auckland.

Over the last 12 months there have been a number of projects the committee have focused on. The first was to identify students working in sleep research. Barbara Galland has done an excellent job in collating this list and as a result we hope to have a varied and top-notch New Investigator session at Sleep in Aotearoa in 2021.

Following on from a Canterbury District Health Board nationwide survey of CPAP provision in the public health service, the NZ committee has set up a group to consider a NZ guideline for CPAP provision. We hope that this will reduce inequities in treatment accessibility within New Zealand.

The Committee has also committed to support the development of a Māori sleep health report. A team of Māori health professionals and researchers will create terms of reference for this document and make recommendations on future sleep health needs for Māori. The terms of reference from the team will include an agreed upon set of principles to guide their work, including those articulated in Kaupapa Māori research methodology such as rangatiratanga (sovereignty), manaakitanga (care) and kaitiakitanga (guardianship).

The committee also supported the development of an online learning tool for paediatric oximetry.

The Sleep Health Foundation New Zealand and ASA’s New Zealand Branch have formalised reciprocal representation observer roles to better support sleep health in New Zealand.

Dr Angela Campbell

New Zealand Branch Chair



Annual Report ANZSSA Representative

The Australian and New Zealand Sleep Science Association (ANZSSA) is the new name for ASTA - same members, same values, with a new structure.

The ANZSSA held their inaugural Annual General Meeting on 25 August 2020 and the first board of directors was elected:

President - **Tom Churchward**

Immediate Past President - **Kerri Melehan**

Vice President - **Nicole Verginis**
(Education)

Secretary - **Anne-Marie Adams**
(Communications)

Treasurer - **Phil Teuwen**
(Finance)

Teanau Roebuck
(Conference)

Scott Coussens
(Research and Grants Portfolio)

Alison Teare
(Membership and Regional Representation)

Warren Ruehland
(Professional Standards Portfolio)

Ross McLachlan
(Policy and Governance Portfolio)

Other key representative roles were appointed with Teanau Roebuck representing ANZSSA on the ASA Board and Kelli Rixon and Andrew Perkins taking responsibility for representation with the Australian Council for Clinical Physiologists.

Key goals for ANZSSA include:

- Success of the ANZSSA Sleep Science Summit and ASA Sleep Week
- The establishment of an Australian Certification Exam (to complement the NZ exam already in place)
- Increasing online sleep science educational content
- Enhancing links to regional and remote services.

ANZSSA looks forward to building on the long-standing, proud, and strong association with the ASA, including contributing to the success of Sleep Week and looking forward to the 2021 Annual Scientific Meeting. ANZSSA notes the need to renew the Memorandum of Understanding regarding combined scientific meetings between our two associations. ANZSSA looks forward to discussing this issue, along with other important topics that we share in common.

Ms Teanau Roebuck
ANZSSA Representative



financial report

FOR THE YEAR ENDED 30 JUNE 2020

Liability limited by a scheme approved under Professional Standards Legislation

Index

Directors' report

Auditor's independence declaration

Statement of profit or loss and other comprehensive income

Statement of financial position

Statement of changes in equity

Statement of cash flows

Notes to the financial statements

Directors' declaration

Auditor's report



114/30 Campbell Street Blacktown NSW 2148

T +61 (0)2 9920 1968 | F +61 (0)2 9672 3884

E admin@sleep.org.au | www.sleep.org.au | ABN 51 138 032 014

Directors' Report

The directors present their report on the company for the financial year ended 30 June 2020.

Information on Directors

The names of each person who has been a director during the year and to the date of this report are:

Peter Raymond Eastwood

Ching Li Chai-Coetzer

Andrew Gikas

Alan Charles Young

Nathaniel Stuart Marshall

Sutapa Mukherjee

Angela Jane Campbell

Directors appointed 19 October 2019:

Jennifer Walsh

Denise O'Driscoll

Teanau Roebuck

Directors resigned 19 October 2019:

Danny Joel Eckert

Maria Kristina Kairaitis

Marcus McMahan

Kerri Melehan

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

Operating Results

The loss of the company amounted to \$151,474 (2019 profit: \$5,086).

Auditor's Independence Declaration

The lead auditor's independence declaration in accordance with section 307C of the *Corporations Act 2001*, for the year ended 30 June 2020 has been received and can be found on the following page.

Signed in accordance with a resolution of the Board of Directors:

Director:



Alan Young

Director:



Nathaniel Marshall

Dated this 23rd day of September 2020

Significant Changes in State of Affairs

The COVID-19 pandemic had immediate impact on operations as the 2020 annual conference was postponed to 2021, and group meetings of members for educational and networking purposes have only been able to take place in the virtual environment. The downturn in financial markets has had a small negative impact on investment results but it is expected that this impact will be able to be reversed over time as markets recover. To compensate for the inability to meet in person, a program of online educational webinars, and an online conference – Sleep Week – were organised. It is not clear what the medium or longer term impact of the pandemic will be.

Principal Activities

The principal activities of the company during the financial year were:

- Drawing up of clinical standards and guidelines
- Overseeing training in the area of clinical sleep medicine
- Provision of quality assurance through credentialing of sleep services, together with the National Association of Testing Authorities (NATA)

- Organisation of an Annual Scientific Meeting, where the latest practice and research is showcased.
- Advocacy with Government and Department of Health

No significant change in the nature of the company's activity occurred during the financial year.

Events After the Reporting Date

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the company, the results of those operations, or the state of affairs of the company in future financial years.

Environmental Issues

The company's operations are not regulated by any significant environmental regulations under a law of the Commonwealth or of a state or territory of Australia.

Indemnification and Insurance of Officers and Auditors

No indemnities have been given or insurance premiums paid, during or since the end of the financial year, for any person who is or has been an officer or auditor of the company.



Auditor's Independence Declaration

UNDER SECTION 307C OF THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF AUSTRALASIAN SLEEP ASSOCIATION

I hereby declare, that to the best of my knowledge and belief, during the financial year ended 30 June 2020 there have been no:

- (i) contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and
- (ii) contraventions of any applicable code of professional conduct in relation to the audit.

Name of Firm: Boyd Audit
Chartered Accountants

Name of Auditor: 
Nathan Boyd
Registered Company Auditor No. 471054

Address: 1.06, 10 Century Circuit, Norwest NSW 2153

Dated this 23rd day of September, 2020

Statement of Profit or Loss and Other Comprehensive Income

for the Year ended 30 June 2020

	Note	2020 \$	2019 \$
Income			
Revenue	3	559,785	518,423
Other income	3	20,755	52,696
		580,540	571,119
Expenditure			
Accountancy expenses		(17,007)	(15,750)
Auditor's remuneration		(9,110)	(8,800)
Depreciation and amortisation expenses		(3,550)	(2,757)
Employee benefits expenses		(394,492)	(344,707)
Other expenses	4	(253,466)	(213,127)
Current year surplus before income tax		(97,085)	(14,022)
Tax expense		–	–
Net current year loss		(97,085)	(14,022)
Other comprehensive income			
Fair value remeasurement gains/(losses) on available-for-sale financial assets		(54,389)	19,108
Other comprehensive income for the year		(54,389)	19,108
Total comprehensive income for the year		(151,474)	5,086

The accompanying notes form part of these financial statements.

Statement of Financial Position

as at 30 June 2020

	Note	2020 \$	2019 \$
ASSETS			
Current Assets			
Cash and cash equivalents	5	245,138	293,818
Trade and other receivables	6	238,426	145,694
TOTAL CURRENT ASSETS		483,564	439,512
Non-current assets			
Financial assets	7	841,305	1,015,729
Property, plant and equipment	8	12,113	15,663
TOTAL NON-CURRENT ASSETS		853,418	1,031,392
TOTAL ASSETS		1,336,982	1,470,904
LIABILITIES			
Current Liabilities			
Trade and other payables	9	534,676	453,391
Provisions	10	14,690	66,935
TOTAL CURRENT LIABILITIES		549,366	520,326
Non-current Liabilities			
Provisions	10	12,165	23,653
TOTAL NON-CURRENT LIABILITIES		12,165	23,653
TOTAL LIABILITIES		561,531	543,979
NET ASSETS (LIABILITIES)		775,451	926,925
EQUITY			
Retained surplus	11	775,451	926,925
TOTAL EQUITY		775,451	926,925

The accompanying notes form part of these financial statements.

Statement of Changes in Equity

for the Year ended 30 June 2020

	Note	Retained earnings \$	Total \$
Balance at 1 July 2018		955,149	955,149
Profit attributable to members of the entity		5,086	5,086
Prior year income recognised as a liability	11	(33,310)	(33,310)
Balance at 30 June 2019		926,925	926,925
Loss attributable to members of the entity		(151,474)	(151,474)
Balance at 30 June 2020		775,451	775,451

Statement of Cash Flows

for the Year ended 30 June 2020

	Note	2020 \$	2019 \$
Cash Flows from Operating Activities			
Membership fees received		312,589	161,147
Conference income received		102,401	194,836
Grant income		45,000	49,460
Other income received		153,945	92,143
Payments to suppliers, employees & others		(816,534)	(584,607)
Interest received		3,437	3,489
Net cash provided by (used in) operating activities	12	(199,162)	(83,532)
Cash Flows from Investing Activities			
Proceeds from sale of available-for-sale investments		409,959	251,093
Dividends received from investments		62,236	98,606
Payments for property, plant and equipment		–	(5,012)
Payments for available-for-sale investments		(321,713)	(374,608)
Net cash provided by (used in) investing activities		150,482	(29,921)
Net increase in cash held		(48,680)	(113,453)
Cash at beginning of financial year		293,818	407,271
Cash at end of financial year	5	245,138	293,818

The accompanying notes form part of these financial statements.

Notes to the Financial Statements

for the Year ended 30 June 2020

The financial statements cover the business of Australasian Sleep Association as an individual entity, incorporated and domiciled in Australia. Australasian Sleep Association is a company limited by guarantee.

The financial statements were authorised for issue on 23 September 2020 by the directors of the company.

1 Basis of Preparation

The Company is non-reporting since there are unlikely to be any users who would rely on the general purpose financial statements.

The special purpose financial statements have been prepared in accordance with the significant accounting policies described below and do not comply with any Australian Accounting Standards unless otherwise stated.

The financial statements have been prepared on an accruals basis and are based on historical costs modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

The significant accounting policies adopted in the preparation of these financial statements are presented below and are consistent with prior reporting periods unless otherwise stated.

2 Summary of Significant Accounting Policies

Property, Plant and Equipment

Each class of property, plant and equipment is carried at cost or fair value less, where applicable, any accumulated depreciation and impairment.

Plant and equipment

Plant and equipment are measured using the cost model.

Depreciation

Property, plant and equipment excluding freehold land, is depreciated on a straight line basis over the asset's useful life to the Company, commencing when the asset is ready for use.

Leased assets and leasehold improvements are amortised over the shorter of either the unexpired period of the lease or their estimated useful life.

The depreciation rates used for each class of depreciable asset are shown below:

Plant & Equipment **20%**

Financial Instruments

Financial instruments are recognised initially using trade date accounting, i.e. on the date that company becomes party to the contractual provisions of the instrument.

On initial recognition, all financial instruments are measured at fair value plus transaction costs (except for instruments measured at fair value through profit or loss where transaction costs expenses as incurred).

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They arise principally through the provision of goods and services to customers but also incorporate other types of contractual monetary assets.

After initial recognition these are measured at amortised cost using the effective interest method, less provision for impairment. Any change in their value is recognised in profit or loss.

The company's trade and most other receivables fall into this category of financial instruments.

In some circumstances, the company renegotiates repayment terms with customers which may lead to changes in the timing of the payments, the company does not necessarily consider the balance to be impaired, however assessment is made on a case-by-case basis.

Available-for-sale financial assets

Available-for-sale financial assets are non-derivative financial assets that do not qualify for inclusion in any of the other categories of financial assets or which have been designated in this category. The company's available-for-sale financial assets comprise listed securities.

All available for sale financial assets are measured at fair value, with subsequent changes in value recognised in other comprehensive income.

Gains and losses arising from financial instruments classified as available-for-sale are only recognised in profit or loss when they are sold or when the investment is impaired.

In the case of impairment or sale, any gain or loss previously recognised in equity is transferred to the profit or loss.

A significant or prolonged decline in value of an available-for-sale asset below its cost is objective evidence of impairment, in this case, the cumulative loss that has been recognised in other comprehensive income is reclassified from equity to profit or loss as a reclassification adjustment. Any subsequent increase in the value of the asset is taken directly to other comprehensive income.

Impairment of Non-Financial Assets

At the end of each reporting period the company determines whether there is an evidence of an impairment indicator for non-financial assets.

Where this indicator exists and regardless for goodwill, indefinite life intangible assets and intangible assets not yet available for use, the recoverable amount of the assets is estimated.

Where assets do not operate independently of other assets, the recoverable amount of the relevant cash-generating unit (CGU) is estimated.

The recoverable amount of an asset or CGU is the higher of the fair value less costs of disposal and the value in use. Value in use is the present value of the future cash flows expected to be derived from an asset or cash-generating unit.

Where the recoverable amount is less than the carrying amount, an impairment loss is recognised in profit or loss.

Reversal indicators are considered in subsequent periods for all assets which have suffered an impairment loss.

Cash and Cash Equivalents

Cash and cash equivalents comprises cash on hand, demand deposits and short-term investments which are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value.

Employee Benefits

Provision is made for the company's liability for employee benefits arising from services rendered by employees to the end of the reporting period. Employee benefits that are expected to be wholly settled within one year have been measured at the amounts expected to be paid when the liability is settled.

Employee benefits expected to be settled more than one year after the end of the reporting period have been measured at the present value of the estimated future cash outflows to be made for those benefits. In determining the liability, consideration is given to employee wage increases and the probability that the employee may satisfy vesting requirements. Cash flows are discounted using market yields on high quality corporate bond rates incorporating bonds rated AAA or AA by credit agencies, with terms to maturity that match the expected timing of cash flows. Changes in the measurement of the liability are recognised in profit or loss.

Provisions

Provisions are recognised when the company has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured.

Revenue and Other Income

Revenue is recognised when the company is entitled to it.

Interest revenue

Interest revenue is recognised using the effective interest rate method.

Rendering of services

Revenue in relation to rendering of services is recognised depends on whether the outcome of the services can be measured reliably. If this is the case then the stage of completion of the services is used to determine the appropriate level of revenue to be recognised in the period. If the outcome cannot be reliably measured, revenue is then recognised to the extent of expenses recognised that are recoverable.

Grant income

Grant income is recognised when the company obtains control over the funds, which is generally at the time of receipt.

If conditions are attached to the grant that must be satisfied before the company is eligible to receive the contribution, recognition of the grant as revenue will be deferred until those conditions are satisfied.

Other income

Other income is recognised on an accruals basis when the company is entitled to it.

Donation income is recognised when the company obtains control over the funds, which is generally at the time of receipt.

Comparative Amounts

Comparatives are consistent with prior years, unless otherwise stated.

Where a change in comparatives has also affected the opening retained earnings previously presented in a comparative period, an opening statement of financial position at the earliest date of the comparative period has been presented.

	2020	2019
	\$	\$
3 Revenue and Other Income		
Income		
Membership subscriptions	257,032	238,075
Conference income	112,728	194,514
Grant received	45,000	9,459
Sleep Health Foundation fees	70,405	67,427
Sundry income	70,771	5,138
Foreign currency translation gains	412	322
Interest received	3,437	3,488
	559,785	518,423
Other income		
Dividend and investment earnings received	20,755	52,696
Fair value remeasurement gains /(losses) on available-for-sale financial assets	(54,389)	19,108
	(33,634)	71,804
	526,151	590,227
4 Expenses		
Advertising & promotion	5,550	9,125
Awards & grants	18,700	16,546
Bank charges	5,015	4,967
Cleaning	3,976	2,730
Consultants fees	29,565	3,504
Conference expenditure	36,785	29,362
Donations	175	452
Insurance	6,359	4,079
Computer & IT service expenses	9,542	9,885
Legal and filing costs	–	1,101
Board meeting expenses	4,065	30,744
Office expenses	7,871	6,286
Printing & stationery	3,164	3,020
Rent & outgoings	33,738	31,129
Research & special projects	81,312	47,903
Staff & board training	378	3,046

	2020	2019
	\$	\$
Subscriptions	2,963	3,277
Telephone & internet	3,875	4,376
Travelling, accommodation & meals	433	1,596
	<u>253,466</u>	<u>213,128</u>

5 Cash and Cash Equivalents

Cash at bank	175,604	128,267
Savings account	218	79,369
Petty cash	31	255
Cash at bank - NZ	17,826	25,990
Cash at bank - JBWere	15,451	24,968
Deposits at call	36,008	34,969
	<u>245,138</u>	<u>293,818</u>

Reconciliation of cash

Cash and Cash equivalents reported in the cash flow statement are reconciled to the equivalent items in the balance sheet as follows:

Cash and cash equivalents	245,138	293,818
	<u>245,138</u>	<u>293,818</u>

6 Trade and Other Receivables

Trade Debtors	20,350	15,601
Prepayments	91,091	23,422
Other debtors	29,737	33,664
Deposits paid	97,248	73,007
	<u>238,426</u>	<u>145,694</u>

7 Financial Assets

Non-Current

Available-for-sale financial assets	841,305	1,015,729
-------------------------------------	---------	-----------

	2020	2019
	\$	\$
8 Property, Plant and Equipment		
Plant and Equipment:		
At cost	51,657	51,657
Accumulated depreciation	(39,544)	(35,994)
Total Plant and Equipment	12,113	15,663
9 Trade and Other Payables		
Trade creditors	15,477	15,819
Credit card liabilities	1,386	1,420
GST liabilities	16,082	8,230
PAYG tax payable	7,381	4,132
Income in advance	146,536	73,815
ASA research grant	40,000	40,000
Other creditors	3,139	5,358
Rob Pierce Fund	34,180	23,809
Helen BearPark Fund	232,562	243,147
Nick Antic Fund	37,933	37,661
	534,676	453,391
10 Provisions		
Current		
Provision for annual leave	14,690	21,920
Provision for long service leave	–	45,015
	14,690	66,935
Non-Current		
Provision for long service leave	12,165	23,653
11 Retained Surplus		
Retained surplus at the beginning of the financial year	926,925	955,149
(Net loss) Net profit attributable to members of the company	(151,474)	5,086
Prior year income recognised as a liability	–	(33,310)
Retained surplus at the end of the financial year	775,451	926,925

In 2019, donations of \$33,310 received in relation to the Nick Antic fund was recognised as income in previous years. During 2019, the board resolved to recognise these donations as funds held by the Company for future awards. Donations have been reclassified as a current liability.

	2020	2019
	\$	\$
12 Cash Flow Information		
Reconciliation of Cash Flow from Operations with Profit after Income Tax		
Profit (Loss) after income tax	(151,474)	5,086
Non-cash flows in profit		
Depreciation expense	3,550	2,757
Gains on available-for-sale investments	32,633	(72,804)
Changes in assets and liabilities		
(Increase)/Decrease in trade and other receivables	(47,964)	(15,944)
(Increase)/Decrease in prepayments	(67,669)	10,385
Increase/(Decrease) in payables	8,505	2,222
Increase/(Decrease) in income in advance	86,990	(32,166)
Increase/(Decrease) in employee provisions	(63,733)	16,932
	(199,162)	(83,532)

13 Company Details

The registered office and principal place of business of the Company is:

Australasian Sleep Association
Suite 114, 30 Campbell Street
Blacktown NSW 2148

14 Members' Guarantee

The entity is incorporated under the Corporations Act 2001 and is a company limited by guarantee. If the company is wound up, the constitution states that each member is required to contribute a maximum of \$10 each towards meeting any outstanding obligations of the company. At 30 June 2020 the number of members was 950 (2019: 945).

Directors' Declaration

The directors have determined that the company is not a reporting entity and that this special purpose financial report should be prepared in accordance with the accounting policies described in Note 1 to the financial statements.

The directors of the company declare that:

1. The financial statements and notes, as set out in this report, for the year ended 30 June 2020 are in accordance with the Corporations Act 2001 and:
 - (a) comply with the Australian Accounting Standards applicable to the company; and
 - (b) give a true and fair view of the financial position of the company as at 30 June 2020 and of its performance for the year ended on that date in accordance with the accounting policies described in Note 1 to the financial statements.
2. In the directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

Director:



Alan Young

Director:



Nathaniel Marshall

Dated this 23rd day of September, 2020



Independent Auditor's Report

TO THE MEMBERS OF AUSTRALASIAN SLEEP ASSOCIATION
ABN 51 138 032 014

Opinion

We have audited the accompanying financial report, being a special purpose financial report, of Australasian Sleep Association which comprises the statement of financial position as at 30 June 2020, the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the directors' declaration by those charged with governance.

In our opinion, the accompanying financial report presents fairly, in all material respects, the financial position of the Company as at 30 June 2020, and of its financial performance and its cash flows for the year then ended in accordance with Australian Accounting Standards.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of our report. We are independent of the Entity in accordance with the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information Other than the Financial Report and Auditor's Report Thereon

Those charged with governance are responsible for the other information. The other information comprises the information included in the Company's annual report for the year ended 30 June 2020, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Report

Management is responsible for the preparation and fair presentation of the financial report in accordance with Australian Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

In preparing the financial report, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.



Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report.

Name of Firm: Boyd Audit
Chartered Accountants

Name of Auditor: 
Nathan Boyd
Registered Company Auditor No. 471054

Address: 1.06, 10 Century Circuit Norwest NSW 2153

Dated this 23rd day of September, 2020



114/30 Campbell Street

Blacktown NSW 2148

T +61 (0)2 9920 1968

F +61 (0)2 9672 3884

E admin@sleep.org.au

www.sleep.org.au

ABN 51 138 032 014